Visão geral da empresa
A commercial-stage medical device company, SeaStar Medical Holding Corporation focuses on developing a proprietary platform therapy designed to mitigate the consequences of hyperinflammation on vital organs within the United States market. The enterprise operates specifically within the Healthcare sector and the Biotechnology industry, positioning itself as a specialized entity in the development of disease-modifying devices such as the selective cytopheretic device (SCD). The company currently maintains a market capitalization of $16.21M, generates $1.23M in annual revenue, and employs a workforce of 17 individuals. These financial figures indicate that SeaStar Medical is a micro-cap biotechnology firm with a relatively small operational footprint, suggesting that its valuation and revenue generation are heavily dependent on the successful commercialization of its proprietary technology rather than broad-based sales volume.
Saúde financeira
SeaStar Medical reported a trailing twelve-month revenue of $1.23M, yet recorded a net income of $-12,150,000, a disparity that reveals a significant gap between top-line sales and bottom-line profitability driven by high operating expenses or losses from R&D activities. The company's EBITDA is listed as N/A, which precludes an immediate assessment of earnings before interest, taxes, depreciation, and amortization without further data. Free cash flow stands at $-9,391,750, indicating that the company is currently consuming cash reserves to fund operations and growth initiatives, thereby limiting its immediate financial flexibility for external expansion or acquisitions. The gross margin is reported at an impressive 95.7%, suggesting that the cost of goods sold is minimal relative to revenue, while the operating margin of -718.1% and profit margin of 0.0% highlight severe inefficiencies in covering operating expenses or the absence of net profit on a pre-tax basis. On the balance sheet, the company holds $11.98M in cash against $525,000 in debt, resulting in a debt-to-equity ratio of 5.04, which implies a leveraged structure where debt significantly outweighs equity capitalization. The current ratio is 3.63, a metric that indicates a robust short-term liquidity position with current assets sufficient to cover short-term obligations more than three times over. Return on Equity is -295.2% and Return on Assets is -80.9%, figures that reveal that management has not yet generated positive returns on the capital invested or assets deployed, reflecting the typical early-stage dynamics of a biotechnology company still seeking product-market fit and commercial viability.
Avaliação de valorização
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is -1.58, a negative metric that implies analysts project continued losses or that valuation models based on future earnings multiples are not yet applicable in a traditional sense for this specific period. The price-to-book ratio is 1.50, suggesting that the market values the company at one and a half times its net asset value, which could reflect intangible assets like intellectual property that are not fully captured on the balance sheet or market expectations of future recovery. The price-to-sales ratio is 13.14, a high multiple for a company with negative earnings, indicating that investors are pricing in significant future growth potential or are willing to pay a premium for the proprietary SCD technology. EV/EBITDA is N/A, reinforcing that traditional enterprise value metrics relying on operating cash flow are not currently calculable given the lack of positive EBITDA. Regarding trading ranges, the stock has a 52-week high of $14.70 and a 52-week low of $2.07, meaning the current price sits significantly below the 52-week high and above the 52-week low, reflecting high volatility within the biotechnology sector. The beta value is -1.19, an anomalous negative figure that suggests the stock price moves inversely to the broader market, exhibiting a volatility profile that is more than 1.19 times that of the market index but in the opposite direction.
Growth & Income
Revenue growth year-over-year is reported at 526.9%, demonstrating a massive expansion in sales, whereas earnings growth is N/A due to the company's net loss, implying that revenue expansion has not yet translated into profitability. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that all earnings, including the losses, are effectively reinvested into the company's operations and research rather than distributed to shareholders. Since the company is a non-dividend payer, the return for investors is entirely capital appreciation driven by the potential success of the selective cytopheretic device and future commercial milestones rather than income generation. The overall growth and income profile characterizes SeaStar Medical as a high-risk, high-volatility investment vehicle that offers no current income stream but provides substantial revenue expansion in a niche medical device market.